Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Psoriasis Drug Fares Well in Late-Stage Trial

By Drug Discovery Trends Editor | August 21, 2014

Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor’s product during late-stage testing on patients with the most common form of the skin disease.
 
The Indianapolis company announced initial results from the research on Thursday and said it plans to submit the drug, ixekizumab, to regulators in the first half of next year. The drugmaker has been pushing to develop new treatments to replace revenue lost due to a wave of patent expirations that have hit top-selling drugs like the antidepressant Cymbalta.
 
In the ixekizumab research, between 31% and 41% of the patients taking its drug achieved clear skin, according to the drugmaker. Overall, those on the drug achieved better levels of skin clearance than patients taking a fake treatment or etanercept, which goes by the brand name Enbrel and is sold by Amgen Inc. and Pfizer Inc.
 
Psoriasis is a chronic disease that occurs when a person’s immune system speeds up the growth cycle of skin cells. The most common form, plaque psoriasis, creates raised, red patches on the skin.
 
Lilly shares climbed 6 cents to $62.07 Thursday before markets opened. The stock had climbed about 22% so far this year, as of Wednesday’s close. The Standard & Poor’s 500 index has climbed about 7% over the same span
 
Date: August 21, 2014
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE